Invest in better immunocontraception with pZP vaccine
Proof of concept complete with over eight studies demonstrating fertility control in wildlife field trials
Clear development pathway
EPA approval expected by 1Q 2019
Revenue can be generated quickly
Positive ROI and ROE
Commercial-ready in one year from closing on funding means cashflow can fund life-cycle management and portfolio expansion to develop vaccines for other species without need for additional dilutive funding
Immunocontraception has immediate application in control of overabundant wild horse populations and urban deer.
Wild horses are not native to the American West. Since they have no natural predators and low mortality rates,their population is growing by roughly 15% per year. In many areas where wild horses are prevalent, their numbers are high enough to upset the delicate balance of the environment.
Urban deer cause billions of dollars of economic damage in densely populated areas. They are difficult to relocate and hunting is not a viable option for population control in densely populated areas.
Use of Proceeds and Development Plan
USE OF PROCEEDS:
Create, standardize and validate manufacturing protocol
Compile submission dossier for EPA
QA:Manufacture batches to affirm antibody response and release specs
Field testing of SpayVac immunocontraception with potential customers
Vaccination of additional overabundant species to expand usage to a greater number of species
Develop other immunocontraceptive vaccines for feral cats and feral dogs
We are seeking investors
SpayVac for Wildlife is seeking to raise approximately $750,000
To receive a non-confidential slide deck, email us
SpayVac for Wildlife Inc.
8617 Lochside Drive, North Saanich, BC V8L1M8, CA & 725 University Row, Suite 439, Madison, WI, 53705 USA